ESR1 and breast cancer: Absence of estrogen receptor, progesterone receptor, and HER2/neu makes TNBC insensitive to some of the most effective therapies available for breast cancer treatment including HER2-directed therapy and endocrine therapies urging the need for identification of new molecular targets in TNBC.